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Background/aim: Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) can in vivo characterize tumor microvascular
environment. The aim of the present study was to reveal the DCE-MRI findings and to determine the correlation between these findings
and immunohistochemical data in head and neck squamous cell carcinoma (HNSCC).
Materials and methods: Thirty-three patients diagnosed with primary HNSCC were evaluated retrospectively. DCE-MRI was
conducted in all cases. CD34, CD105, and ki-67 expressions were analyzed with immunohistochemistry in tissue sections to determine
micro-vessel density and proliferative activity.
Results: The DCE-MRI is a successful technique in distinguishing tumor tissue from normal tissue. It was determined that Ve, Ktrans,
and ki-67 values were significantly higher in high-stage tumors and there were positive correlations between the Ktrans value (by
standard ROI) and CD34 MVDmax and CD34 MVDmean values. No statistically significant correlation was determined between other
parameters in DCE-MRI and immunohistochemical data, and T stage.
Conclusion: DCE-MRI could successfully differentiate tumor tissue in HNSCC. Furthermore, it was observed that DCE-MRI had the
potential to reveal certain immunohistochemical information in vivo.
Key words: Head and neck region, squamous cell carcinoma, magnetic resonance imaging, dynamic contrast enhancement,
immunohistochemical data

1. Introduction
In head and neck squamous cell carcinoma (HNSCC), the
tumor stage is associated with nodal and distant metastases,
local recurrence, and total survival [1–3]. However, since
the biological behavior of HNSCC is variable, patients in
the same tumor stage may have a different prognosis or
may give dissimilar responses to the same treatment [2,3].
Thus, anticipating the prognosis and treatment response
based on the tumor stage alone may not be sufficient.
There is no biomarker in HNSCC with the sensitivity or
specificity to predict histopathological information during
the preoperative period. Angiogenesis is a significant factor
in tumor growth, and it is vital to observe and measure
growth quantitatively to determine the malignant behavior
of the tumor [4]. The quantitative analysis of angiogenesis
could be performed using immunohistochemical
methods and antibodies specific to the antigens found in
vascular endothelium, such as CD34 and/or CD105 [5,6].

Although there are certain limitations, positron emission
tomography can provide practical information, while
perfusion imaging can provide information on capillarity;
however, both methods lack adequate histopathological
details [1,7]. However, dynamic contrast enhanced
magnetic resonance imaging (DCE-MRI) can in vivo
characterize tumor microvascular environment [7,8].
It has been shown in the literature that these techniques
provide data on benign-malignant tumor differentiation
and tumor immunohistochemistry and predict tumor
response to treatment in various malignancies such as the
rectum, breast, prostate, and glial tumors [4,7–10]. Similar
studies were conducted on HNSCC; however, the number
of publications and reported information was insufficient
[1,4,7,11].
The objective of the study was to calculate the
correlation between the parameters of DCE-MRI and the
immunohistochemical findings in HNSCC.
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2. Materials and methods
2.1. Patients
Thirty-six patients diagnosed with primary HNSCC
between December 2018 and June 2020 in our clinic
and who underwent DCE-MRI were evaluated
retrospectively. Three patients were excluded from
the study due to inadequate MRI images. Thirtythree patients (6 women, 27 men; mean age 61.9,
age range: 22–94) were included in the study. Fifteen
patients had a biopsy and 18 had both a biopsy and an
excision (underwent surgical resection). DCE-MRI was
conducted before tissue samples were collected (average
19 days, range: 1–30 days). Exclusion criteria included 1)
patients younger than 18 years, 2) inadequate DCE-MRI
images due to artifacts, 3) tumor treatment prior to DCEMRI, 4) lack of tissue samples for immunohistochemical
evaluation, and 5) the presence of concomitant cancers
in different anatomical regions.
Tumor localization in the oral cavity was observed in
thirteen patients, in the larynx in eleven patients, and in
the oropharynx in nine patients.
For statistical purposes, the cases were divided into
two groups based on the TNM staging system. Patients in
T1 and T2 stages were included in Group 1 (N = 15) and
patients in T3 and T4 stages were included in Group 2 (N
= 18).
The MR examination was conducted with a 1.5 T MR
scanner (Achieva, Philips Medical Systems, Netherlands)
with a head-neck coil.
2.2. DCE-MRI parameters
DCE imaging was performed using the T1W DCE
sequences (T1W Single Shot Turbo Field Echo, matrix
256 × 256). Before the DCE-MRI sequence, T1 mapping
was conducted with two flip angles of 5o and 15o (TR:10
ms and TE:2.4 ms, axial plane, section thickness: 3
mm). T1W DCE sequence that included 50 subsequent

scans in 6 s was conducted before, during, and after
administering an intravenous contrast agent with
gadolinium. Gadoterat Meglumin (Dotarem, Guerbet
Medical Supplies and Devices Pharmaceutical Industry
and Trade Co.) was applied as a contrast agent at a dose
of 0.2 mmol/kg and at the rate of 2 mL/s intravenously in
the forearm with an automatic injector and then 20 mL
saline was injected.
2.3. Analysis of the images
All images were transferred to a software module
(IntelliSpace Portal-v8.2.20820, Philips Medical Systems,
Netherlands) and all measurements were conducted
using the workstation. The Ktrans, Kep, Ve, and iAUC
[Ktrans = volume transfer constant (10–3/dk), Kep =
rate constant reflects the backflow from the tumor to
the vascular system, Ve = extravascular extracellular
space volume ratio (10–3), iAUC = initial area under
the curve] values were calculated with the Tofts Model,
based on population-averaged AIF [12]. Two different 2D
ROI (region of interest) measurements were conducted
in quantitative analysis. 1) Widest section ROI: freehand ROI drawn in the section where the tumor was
the widest, avoiding necrosis areas using conventional
images (Figure 1A). 2) Standard ROI: in lesions larger
than 1 cm, three nonintersecting ROIs of 0.5 cm2 were
drawn and the average of the 3 values was calculated,
while in lesions smaller than 1 cm, a single 0.5 cm2 ROI
was placed in the most solid area (Figure 1B). The normal
tissue measurement was obtained with ROI placed in
normal tissue symmetric to the lesion. Two radiologists
(ten years and five years’ experience in head and neck
oncology), blind to all clinical data, analyzed the images.
The location of the ROI was determined by the joint
decision of the two radiologists. Two measurements
were made from the same location and the average of the
measurements was used for statistical processes.

Figure 1. Schematic drawing of the widest ROI (A) and the standard ROI (B) in
Ktrans map.
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2.4. Immunohistochemical analysis
Immunohistochemical staining of the tissue sections in
paraffin-embedded blocks was conducted, as described
previously, with ki-67 (Roche Diagnostics., prediluted),
CD34 (Roche Diagnostics., prediluted), and CD105
(Cornomics, 1/100 dilution) primary antibodies [6].
Digital images of the sections were evaluated on a computer
via a camera attached to a light microscope. The number
of micro-vessels with CD34 and CD105 antibodies was
determined in 5 hotspots in the sections available at ×10
magnification on the computer screen individually. For
the five regions, the value of the maximum count in one
region and the mean of the counts in five regions were
used in the statistical analysis. Ki-67 index was analyzed
with the same image acquisition and analysis method, and
a total of 2000 cells were counted in hotspot regions for
each case. Micro-vessel density (MVD) was calculated by
dividing the number of identified micro-vessels by the
area under study.

2.5. Statistical analysis
Kolmogorov-Smirnov test was employed to determine the
normal distribution of all data. Pearson and Spearman
correlation tests were employed in data with and without
normal distribution, respectively.
The comparisons between T-stage groups, DCE-MRI,
and immunohistochemical data were determined with the
Mann-Whitney U test.
SPSS 24 software (SPSS Inc, Chicago, IL, USA) was
used in the statistical analysis. p < 0.05 was considered
statistically significant in all analyzes.
3. Results
3.1. DCE-MRI data
It was determined that all DCE-MRI parameters
measured from tumor tissue were significantly higher
when compared to normal tissue (p < 0.01) (Table 1)
(Figure 2).

Figure 2. Comparison of DCE-MRI data of tumor and normal tissues.
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It was determined that there was a positive correlation
between Ktrans and iAUC (r = 0.420, p = 0.015), a negative
correlation between Kep and Ve (r = –0.843, p = 0.000), a
negative correlation between Kep and iAUC (r = –0.488, p
= 0.004), and a positive correlation (r = 0.748, p = 0.000)
between Ve and iAUC with widest section ROI. There was
a positive correlation between Ktrans and Kep (r = 0.399,
p = 0.021), a positive correlation between Ktrans and Ve
(r = 0.540, p = 0.001), and a positive correlation between
Ktrans and iAUC (r = 0.750, p = 0.000) with standard ROI.
While there was no correlation between the Kep and other
parameters, a positive correlation (r = 0.792, p = 0.000)
was determined between Ve and iAUC.
No correlation was identified between the DCE-MRI
data with the widest section ROI and immunohistochemical
analysis. A weak positive correlation was determined
between the Ktrans value, which was obtained with
standard ROI and CD34 MVDmax and CD34 MVDmean
(r = 0.667, p = 0.037 and r = 0.579, p = 0.049, respectively)
(Table 2) (Figure 3).
Based on the T-stage, the mean ki-67 was 61.87 ± 15.92 in
Group 1 and it was 72.30 ± 11.49 in Group 2 (p = 0.03). There

was no statistically significant difference between the two
groups based on MVD parameters (p > 0.05). Ve and Ktrans
values (with standard ROI) was statistically significantly
higher in Group 2 (p = 0.003 and p = 0.048 respectively)
(Figure 4). Furthermore, iAUC value was higher in Group
2; however, the difference was not statistically significant (p
= 0.079). No significant difference was determined between
the DCE-MRI data with the widest section ROI. Other
DCE-MRI parameters did not show statistically significant
differences between the groups.
In addition to the above-mentioned findings, the
analysis of only the patients who underwent excision
surgery demonstrated that the correlation between Ktrans
and CD34 MVD was higher (r = 0.667, p = 0.002 for CD34
MVDmax and r = 0.579, p = 0.001 for CD34 MVDmean),
and there was a positive correlation between Ktrans and
CD105MVD max-mean (r = 0.549, p = 0.018 and r =
0.560, p = 0.016 respectively).
3.2. Immunohistochemical data
Immunohistochemical data for tumor tissues are presented
in Table 3.

Table 1. DCE-MRI data with the widest section ROI.
Tumor tissue

Normal tissue

P-value

Mean

Range

Mean

Range

Ktrans

0.059

0.038–0.135

0.020

0.005–0.063

<0.001

Kep

0.372

0.028–1.431

0.176

0.009–0.442

0.000

Ve

0.181

0.050–1.850

0.107

0.014–1.960

0.006

iAUC

118.54

61.63–452.63

53.18

5.76–124.03

0.000

Table 2. Correlation between DCE-MRI and immunohistochemical data.
Ki-67

CD34 MVDmax

CD34 MVDmean

CD105 MVDmax

CD105 MVDmean

r = 0.222* (p = 0.21)

r = 0.205* (p = 0.25)

r = 0.242* (p = 0.17)

Ktrans
Widest section ROI

r = –0.019* (p = 0.91) r = 0.152* (p = 0.40)

Standard ROI

r = 0.089** (p = 0.62) r = 0.364** (p = 0.037) r = 0.346** (p = 0.049) r = 0.236** (p = 0.18) r = 0.307** (p = 0.08)

Kep
Widest section ROI

r = –160* (p = 0.37)

Standard ROI

r = 0.154* (p = 0.19)

r =219* (p=0.22)

r = 0.054* (p = 0.76)

r = 0.109* (p = 0.54)

r = –0.023* (p = 0.90) r = 0.235* (p = 0.18)

r = 0.237* (p=0.18)

r = –0.008* (p = 0.96) r = 0.066* (p = 0.71)

Widest section ROI

r = 0.124* (p = 0.49)

r = –0.059* (p = 0.74)

r = –0.110* (p = 0.52)

r = 0.019* (p = 0.91)

r = 0.011* (p = 0.95)

Standard ROI

r = 0.060* (p = 0.74)

r = 0.122* (p = 0.50)

r = 0.119* (p = 0.51)

r = 0.245* (p = 0.16)

r = 0.206* (p = 0.25)

Widest section ROI

r = 0.191* (p = 0.28)

r = –0.073* (p = 0.68)

r = –0.129* (p = 0.47)

r = 0.047* (p = 0.79)

r = 0.024* (p = 0.89)

Standard ROI

r = 0.092* (p = 0.60)

r = 0.140* (p = 0.43)

r = 0.158* (p = 0.38)

r = 0.278* (p = 0.11)

r = 0.278* (p = 0.11)

Ve

iAUC

* Spearman correlation test; **Pearson correlation test
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Figure 3. Correlation curve of CD34 MVDmax and CD34 MVDmean parameters with Ktrans (by standard ROI).

Figure 4. Comparison of Ve, Ktrans, and ki-67 values in Groups 1 and 2.

Table 3. Immunohistochemical data.
Parameter

Mean ± sd

Median

Range

Ki-67 (%)

67.56 ± 14.45

67.70

34.10–94.40

CD34 MVDmean

65.29 ± 23.68

65.38

21.15–123.08

CD34 MVDmax

79.52 ± 28.32

74.61

23.07–133.84

CD105 MVDmean

51.09 ± 24.14

46.46

19.23–115.85

CD105 MVDmax

60.28 ± 27.37

59.23

17.69–128.46

4. Discussion
The present study demonstrated that all DCE-MRI
parameters were significantly higher in tumor tissue
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compared to normal tissue. There were also several
significant associations between DCE-MRI parameters
with immunohistochemical data.
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Previously, several studies reported (Chen et al. in 25
patients, Bisdas et al. in 27 patients) that Ktrans, Kep, and Ve
parameters were significantly higher in tumor tissue than
in normal tissue, similar to our results [13,14]. However,
only a few studies investigated the relationships between
DCE-MRI and immunohistochemical data in HNSCC.
Surov et al. reported a negative correlation between Ve
and mean microvascular diameter and between ki-67 and
Ktrans in 16 HNSCC patients [11]. The study of Dong et
al. evaluating 42 patients with HNSCC concluded that
the Ktrans, Ve, and iAUC were significantly higher in
poorly differentiated HNSCC patients compared to welldifferentiated patients. [1]. In this study, while CD34
MVDmax and CD34 MVDmean values were correlated
with Ktrans, no correlation was observed between other
DCE-MRI with immunohistochemical parameters. This
may be due to the fact that the measurements were made
with 2D manual ROI instead of 3D histogram analysis, as
in some other studies. Furthermore, another reason for
this may be the disruption of blood flow physiology due
to vessels of different lengths and diameters in the tumor
tissue, which contain tortuous and arteriovenous shunts;
and consequently, the presence of high angiogenic activity
in areas with low vessel density. It was also reported that
MVD measurements depended on the characteristics of
the postoperative tissue or biopsy material and different
densities could be observed in other areas [10]. As a
matter of fact, to eliminate this limitation, only the
histopathological data obtained from the excision material
were evaluated and it was observed that the correlation
between DCE-MRI data and MVD data became stronger.
Although the clinical role of MVD in HNSCC is not fully
known, the prediction of this immunohistochemical
parameter with DCE-MRI data such as Ktrans is still
important.
Our study revealed that permeability data of tumor
vascularity demonstrated a complex relationship.
There are limited studies to draw solid conclusions on
the DCE-MRI parameter that can be used to predict
immunohistochemical data in HNSCC. In the literature,
the most important parameter seems to be Ktrans, which
has been associated with poor prognosis and molecular
determinants of tumor hypoxia [7,13,15]. Similarly, in our
study, ktrans value was found to be significantly higher
in tumors with high T stage. However, the correlation
between Ktrans and immunohistochemical data could not
be clearly defined.
Usually, the vascular and extravascular-extracellular
spaces are expected to be proportional. However, this
ratio would degrade to provide more oxygen to the tumor
tissue; and thus, the Ve parameter would be higher in
malignant tumors. We found that Ve values were higher
in Group 2, and it was quite promising that the T stage

could be predicted with DCE-MRI. In addition, although
the iAUC value is not statistically significant, in high-stage
tumors found to be higher. In the study of Chen et al. with
42 patients diagnosed with esophageal cancer, according
to the histogram analysis of the whole lesion, the value
of Ve was found to be significantly higher in T3 tumors
compared to T1-T2 tumors [16]. In the study of Huang
et al. with 45 patients diagnosed with nasopharyngeal
cancer, the relationship between the quantitative and
semiquantitative data of DC-MRI obtained from the whole
lesion and the tumor stage was examined. In this study,
mean Ve and iAUC data were found to be significantly
higher in stage T3-T4 tumors compared to T1-T2. There
was no significant difference in Ktrans and Kep parameters
[17]. In high-stage tumors, neovascularization, perfusion,
and permeability between the blood pool and the tumor
are higher compared to low-stage tumors. This explains
its further development, greater accumulation of contrast
agents in the tumor and increased iAUC [10,14]. However,
as mentioned above, the semiquantitative methods reflect
the signal-intensity curve rather than directly reflecting
the contrast agent concentration. These parameters can
be easily affected by the MRI protocol and the intrinsic
properties of the tissue and are the main restrictive features
of the technique. However, the relationship between iAUC
and tumor physiology is complicated, and the feature
represented by the tumor is not clear since it may be
affected by different physiological processes [18].
It has been reported in the literature that ki-67 may
be a prognostic factor in various tumors [19]. Although
there are conflicting results in HNSCC, there are studies
showing the correlation between ki-67 and T stage in
laryngeal squamous cell carcinoma [20]. In our research,
ki-67 was significantly higher in high-stage tumors
compared to low-stage tumors.
4.1. Limitations of DCE-MRI technique
DCE-MRI method also has certain limitations. The
employment of this technique in HNSCC is in early
stages; thus, the technique is not fully standardized yet.
Too many factors (such as MRI device, arterial input
function measurement method, ROI and parameter
selection, pharmacokinetic model variations, etc.) may
affect the reliability of the results, which could lead to
different results in different institutions [18,21]. Another
difficulty in determining the correlations between DCEMRI parameters and tumor angiogenesis-histology was
the tumor heterogeneity at the subvoxel level. In analyzing
and interpreting the data, it is necessary to consider the
heterogeneity of the tumor. In DCE-MRI studies, userdefined ROIs are generally employed, and this is prone to
partial volume average errors. The partial volume average
assumes that the kinetic parameters of all pixels are equal,
ignoring tumor heterogeneity. Thus, certain authors
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recommended verifying DCE-MRI imaging parameters
with measurements conducted with various 3D ROIs
[1,22]. In future studies focusing on optimal DCEMRI parameters to predict the immunohistochemistry
in HNSCC, the ROI method should be used for this
parameter and the standard method should be used to
verify the data. For this purpose, in 2007, RSNA organized
the Quantitative Imaging Biomarkers Alliance® (QIBA) to
unite researchers, healthcare professionals, and industry
to advance quantitative imaging and the use of imaging
biomarkers in clinical trials and clinical practice. QIBA
provides guidelines for data collection, analysis, and
quality control in DCE-MRI and works on standardization
of the technique [23].
4.2. Limitations of study
The present study had certain limitations: 1) Thirty-three
patients were included. Studies with a higher number
of cases are required to improve the results’ accuracy
and reveal other possible correlations between DCEMRI and immunohistochemistry. 2) In certain patients,
immunohistochemical analysis was conducted only
with biopsy material. Thus, it was likely that DCE -MRI
measurements were conducted on sites other than the
biopsied area, and as a result, DCE -MRI findings may
not fully reflect tumor immunohistochemistry. 3) A 3D
histogram analysis covering all tumor sections would

provide a more reliable and efficient representation of the
whole lesion. However, our workstation did not support
the 3D histogram analysis. 4) All HNSCCs were included
in our study. However, angiogenesis, tumor behavior, and
technical methods may vary in HNSCC; thus, studies
focusing on specific subsites may provide more accurate
findings. 5) The lack of interobserver variability is another
limitation of the study.
DCE-MRI can successfully differentiate the tumor
tissue in HNSCC. Furthermore, it was observed that
DCE-MRI is a method potentially revealing some
immunohistochemical information in vivo. However, its
technical development and clinical use are still in the early
stages. With standardized image acquisition techniques,
data analysis and reporting systems, and multicenter and
adequately powered validation studies, the significance of
DCE-MRI in HNSCC imaging will become more apparent.
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